Antidepressants increase melatonin levels, but it is still unclear whether this effect is related to the improvement of depressive symptoms or to unrelated pharmacological action of antidepressants. To answer this question, the effect of antidepressants on 6-sulphatoxymelatonin (aMT6s), the main melatonin urinary metabolite, was examined in drug-free depressed patients – most of them antidepressant-naive. aMT6s was evaluated in 34 depressed patients, before and after 8 weeks of placebo (n = 12) or antidepressant (n = 22; fluoxetine, duloxetine or Hypericum perforatum). Both groups showed an improvement of depressive symptoms after treatment compared to baseline (Hamilton Depression scores): 17.0 ± 1.4 vs. 9.0 ± 2.8, P = 0.007 for placebo, and 18.6 ± 1.1 vs. 11.8 ± 1.6, P < 0.001 for antidepressants). After treatment, aMT6s levels increased after antidepressants (P < 0.01), but not after placebo (P > 0.05). As depressive symptoms improved both in patients taking antidepressant and in those taking placebo, but an effect of antidepressants could only be seen in those taking antidepressants, we suggest that melatonin changes after antidepressants are more likely due to a pharmacological action of these drugs on melatonin secretion.
American Psychiatry Association (1994) Diagnostic and Statistical of Mental Disorders, fourth ed.Washington, DC: APA Press, Inc.
2.
Arendt J (1986) Assay of melatonin and its metabolites: results in normal and unusual environments.J Neural Transm21: 11–33.
3.
Baldwin D Broich K Fritze J Kasper S Westenberg H Moller HJ (2003) Placebo-controlled studies in depression: necessary, ethical and feasible.Eur Arch Psychiatry Clin Neurosci253: 22–28.
4.
Berlin I Touitou Y Guillemant S Danjou P Puech AJ (1995) Beta-adrenoceptor agonists do not stimulate daytime melatonin secretion in healthy subjects. A double blind placebo controlled study.Life Sci56: L325–L331.
5.
Burgess HJ Fogg LF Young MA Eastman CI (2004) Bright light therapy for winter depression–is phase advancing beneficial?Chronobiol Int21: 759–775.
6.
Carvalho LA Gorenstein C Moreno RA Markus RP (2006) Melatonin levels in drug-free patients with major depression from the southern hemisphere.Psychoneuroendocrinology31: 761–768.
7.
Cook MR Graham C Kavet R Stevens RG Davis S Kheifets L (2000) Morning urinary assessment of nocturnal melatonin secretion in older women.J Pineal Res28: 41–47.
8.
Dworkin RH Katz J Gitlin MJ (2005) Placebo response in clinical trials of depression and its implications for research on chronic neuropathic pain.Neurology65: S7–S19.
9.
Ferreira ZS Fernandes PA Duma D Assreuy J Avellar MC Markus RP (2005) Corticosterone modulates noradrenaline-induced melatonin synthesis through inhibition of nuclear factor kappa B.J Pineal Res38: 182–188.
10.
Friedman E Yocca FD Cooper TB (1984) Antidepressant drugs with varying pharmacological profiles alter rat pineal beta adrenergic-mediated function.J Pharmacol Exp Ther228: 545–550.
11.
Gobert A Rivet JM Cistarelli L Melon C Millan MJ (1999) Buspirone modulates basal and fluoxetine-stimulated dialysate levels of dopamine, noradrenaline and serotonin in the frontal cortex of freely moving rats: activation of serotonin1A receptors and blockade of alpha2-adrenergic receptors underlie its actions.Neuroscience93: 1251–1262.
12.
Golden RN Markey SP Risby ED Rudorfer MV Cowdry RW Potter WZ (1988) Antidepressants reduce whole-body norepinephrine turnover while enhancing 6-hydroxymelatonin output.Arch Gen Psychiatry45: 150–154.
13.
Griefahn B Brode P Blaszkewicz M Remer T (2003) Melatonin production during childhood and adolescence: a longitudinal study on the excretion of urinary 6-hydroxymelatonin sulfate.J Pineal Res34: 26–31.
14.
Hamilton M (1960) A rating scale for depression.J Neurol Neurosurg Psychiatry23: 56–62.
15.
Hariharasubramanian N Nair NP Pilapil C Isaac I Quirion R (1986) Effect of imipramine on the circadian rhythm of plasma melatonin in unipolar depression.Chronobiol Int3: 65–69.
16.
Hartter S Wang X Weigmann H Friedberg T Arand M Oesch F (2001) Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin.J Clin Psychopharmacol21: 167–174.
17.
Karpa KD Cavanaugh JE Lakoski JM (2002) Duloxetine pharmacology: profile of a dual monoamine modulator.CNS Drug Rev8: 361–376.
18.
Kennedy SH Brown GM (1992) Effect of chronic antidepressant treatment with adinazolam and desipramine on melatonin output.Psychiatry Res43: 177–185.
19.
Klante G Brinschwitz T Secci K Wollnik F Steinlechner S (1997) Creatinine is an appropriate reference for urinary sulphatoxymelatonin of laboratory animals and humans.J Pineal Res23: 191–197.
20.
Kripke DF Jean-Louis G Elliott JA Klauber MR Rex KM Tuunainen A Langer RD (2004) Ethnicity, sleep, mood, and illumination in postmenopausal women.BMC Psychiatry4: 8.
21.
Kripke DF Youngstedt SD Rex KM Klauber MR Elliott JA (2003) Melatonin excretion with affect disorders over age 60.Psychiatry Res118: 47–54.
22.
Lewy AJ Bauer VK Cutler NL Sack RL Ahmed S Thomas KH Blood ML Jackson JM (1998) Morning vs evening light treatment of patients with winter depression.Arch Gen Psychiatry55: 890–896.
23.
Lucas RA (1992) The human pharmacology of fluoxetine.Int J Obes Relat Metab Disord16(Suppl. 4): S49–S54.
24.
Ma X Idle JR Krausz KW Gonzalez FJ (2005) Metabolism of melatonin by human cytochromes p450.Drug Metab Dispos33: 489–494.
25.
Miguez JM Simonneaux V Pevet P (1995) Evidence for a regulatory role of melatonin on serotonin release and uptake in the pineal gland.J Neuroendocrinol7: 949–956.
26.
Miller HL Ekstrom RD Mason GA Lydiard RB Golden RN (2001) Noradrenergic function and clinical outcome in antidepressant pharmacotherapy.Neuropsychopharmacology24: 617–623.
27.
Montgomery SA Asberg M (1979) A new depression scale designed to be sensitive to change.Br J Psychiatry134: 382–389.
28.
Moore RY (1996) Neural control of the pineal gland.Behav Brain Res73: 125–130.
29.
Nathan PJ (2001) Hypericum perforatum (St John’s Wort): a non-selective reuptake inhibitor? A review of the recent advances in its pharmacology.J Psychopharmacol15: 47–54.
30.
Palazidou E Papadopoulos A Ratcliff H Dawling S Checkley SA (1992a) Noradrenaline uptake inhibition increases melatonin secretion, a measure of noradrenergic neurotransmission, in depressed patients.Psychol Med22: 309–315.
31.
Palazidou E Skene D Arendt J Everitt B Checkley SA (1992b) The acute and chronic effects of (+) and (−) oxaprotiline upon melatonin secretion in normal subjects.Psychol Med22: 61–67.
32.
Paykel ES (1999) The Hamilton Scales.New York: Springer-Verlag.
33.
Penny R Stanczyk F Goebelsmann U (1987) Melatonin: data consistent with a role in controlling ovarian function.J Endocrinol Invest10: 499–505.
34.
Rabe-Jablonska J Szymanska A (2001) Diurnal profile of melatonin secretion in the acute phase of major depression and in remission.Med Sci Monit7: 946–952.
35.
Rubin RT Heist EK McGeoy SS Hanada K Lesser IM (1992) Neuroendocrine aspects of primary endogenous depression. XI. Serum melatonin measures in patients and matched control subjects.Arch Gen Psychiatry49: 558–567.
36.
Simonneaux V Ribelayga C (2003) Generation of the melatonin endocrine message in mammals: a review of the complex regulation of melatonin synthesis by norepinephrine, peptides, and other pineal transmitters.Pharmacol Rev55: 325–395.
37.
Spitzer RL Williams JB Gibbon M First MB (1992) The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description.Arch Gen Psychiatry49: 624–629.
38.
Steardo L Monteleone P Trabace L Cannizzaro C Maj M Cuomo V (2000) Serotonergic modulation of rat pineal gland activity: in vivo evidence for a 5-Hydroxytryptamine(2C) receptor involvement.J Pharmacol Exp Ther295: 266–273.
39.
Stewart JW Halbreich U (1989) Plasma melatonin levels in depressed patients before and after treatment with antidepressant medication.Biol Psychiatry25: 33–38.
40.
Thompson C Mezey G Corn T Franey C English J Arendt J Checkley SA (1985) The effect of desipramine upon melatonin and cortisol secretion in depressed and normal subjects.Br J Psychiatry147: 389–393.
41.
Von Bahr C Ursing C Yasui N Tybring G Bertilsson L Rojdmark S (2000) Fluvoxamine but not citalopram increases serum melatonin in healthy subjects – an indication that cytochrome P450 CYP1A2 and CYP2C19 hydroxylate melatonin.Eur J Clin Pharmacol56: 123–127.
42.
Wehr TA (2001) Photoperiodism in humans and other primates: evidence and implications.J Biol Rhythms16: 348–364.
43.
Williams JB Gibbon M First MB Spitzer RL Davies M Borus J (1992) The Structured Clinical Interview for DSM-III-R (SCID). II. Multisite test-retest reliability.Arch Gen Psychiatry49: 630–636.
